Importantly, elevated RASD2 expression strongly correlated with aggressive clinicopathological features, including lymph node metastasis, extrathyroidal extension, and advanced TNM staging. This evidence concerns the gene RASD2 and metastatic malignant neoplasm in the lymph nodes.